Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$195.83 USD

195.83
1,434,682

-0.99 (-0.50%)

Updated Oct 3, 2024 12:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View

by Zacks Equity Research

AbbVie (ABBV) beats second-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.

Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 5%

by Zacks Equity Research

Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 2.26% and 1.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AstraZeneca (AZN) Jumps: Stock Rises 5.7%

by Zacks Equity Research

AstraZeneca (AZN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

AbbVie (ABBV) Beats Q2 Earnings and Revenues, Shares Up

by Zacks Equity Research

AbbVie's (ABBV) second-quarter 2019 earnings and revenues both beat estimates. The company raised its guidance for adjusted earnings in 2019.

Christopher Vargas headshot

Buy Merck & Co (MRK) Stock Ahead of Q2 Earnings Report?

by Christopher Vargas

Merck & Co (MRK) is set to report its fiscal 2019 second quarter earnings before the opening bell on July 30th.

Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

by Zacks Equity Research

Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

Should You Buy AbbVie (ABBV) Ahead of Earnings?

by Zacks Equity Research

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised

by Zacks Equity Research

Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)

by Mitchell Moore

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings

by Mitchell Moore

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.

Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.

Sanghamitra Saha headshot

Use Rising P/E Strategy to Buy 5 Winning Stocks

by Sanghamitra Saha

Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.

Kinjel Shah headshot

Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright

by Kinjel Shah

The Zacks Large Cap Pharmaceuticals industry underperforms the sector and S&P 500. However it ranks in the top 19% of more than 250 Zacks industries.

Zachary Stutler headshot

AbbVie (ABBV) Set to Report Q2 Earnings: What to Expect

by Zachary Stutler

AbbVie (ABBV) is set to release its Q2 earnings before market open on Friday. AbbVie stock has performed very poorly YTD, falling 26%.

Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View

by Zacks Equity Research

Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.

Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings?

by Zacks Equity Research

Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.

Top Ranked Value Stocks to Buy for July 23rd

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, July 23rd

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, AbbVie (ABBV) closed at $68, marking a -0.79% move from the previous day.

Sweta Killa headshot

Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy

by Sweta Killa

With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.

Can Allergan (AGN) Keep the Earnings Streak Alive in Q2?

by Zacks Equity Research

While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.

Is a Beat in Store for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.

AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.